Antimicrobial Susceptibility Testing Market by Product Type, Method, Type, Application, End-User

Description

List of Tables

[185 Pages Report] The Antimicrobial Susceptibility Testing Market size was estimated at USD 3.61 billion in 2022 and expected to reach USD 3.81 billion in 2023, at a CAGR 5.80% to reach USD 5.67 billion by 2030.

Global Antimicrobial Susceptibility Testing Market

KEY MARKET STATISTICS
Base Year [2022]	USD 3.61 billion
Estimated Year [2023]	USD 3.81 billion
Forecast Year [2030]	USD 5.67 billion
CAGR (%)	5.80%

Antimicrobial Susceptibility Testing Market - IMG1

Antimicrobial susceptibility testing (AST) determines the effectiveness of antibiotics or other antimicrobial drugs against microorganisms such as bacteria, fungi, and viruses. This testing method is an essential tool for guiding the selection of appropriate antibiotics used in treating infectious diseases and monitoring the emergence of drug-resistant strains of microorganisms. The market is experiencing growth due to various factors, including the rising incidence of infectious disorders, the growing adoption of point-of-care testing facilities, and the surging demand for prompt and precise detection of antibiotic resistance. However, challenges affecting the expansion of the AST market comprise high costs associated with advanced technologies such as molecular diagnostics instruments or automated systems, limiting their adoption by small-scale laboratories. In addition, limited access to robust healthcare infrastructure in developing countries, insufficient funding for research and development (R&D), lack of skilled professionals in the field, and variation in regulatory policies among different regions affecting market entry or expansion efforts are the additional obstacles affecting the expansion of the market. Additionally building partnerships between industry stakeholders such as diagnostic manufacturers, healthcare providers researchers and pharmaceutical companies can streamline processes while driving advancements in AST technologies. Moreover, the increasing demand for accurate and timely diagnosis of infectious diseases is expected to create lucrative opportunities for the market, particularly with the technological advancement in disease diagnosis testing techniques and the introduction of new genomic identification methods.

Regional Insights

The Americas and Europe are significant regions in the global antimicrobial susceptibility testing market due to the rise in infectious diseases and advanced healthcare infrastructure. The Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN), which tracks antimicrobial resistance patterns in nationwide healthcare facilities, promotes AST adoption while ensuring high-quality data collection. In Latin America, significant progress is observed in the field of antimicrobial susceptibility testing (AST), with countries such as Brazil adopting and executing guidelines established by the Clinical & Laboratory Standards Institute (CLSI). This crucial development contributes to the global efforts in combating antimicrobial resistance, thereby ensuring effective treatment options for bacterial infections. Furthermore, the European Centre for Disease Prevention and Control (ECDC) plays a pivotal role in tracking resistance patterns across Europe through its European Antimicrobial Resistance Surveillance Network (EARS-Net). The Asia-Pacific (APAC) is expected to experience substantial growth in the market due to rising awareness about infectious diseases, increasing healthcare expenditure, and emerging drug-resistant microorganisms. China, Japan, and India are the major markets for antimicrobial susceptibility testing within the Asia-Pacific. These nations have a high burden of infectious diseases and a large population, which is expected to drive the demand for AST products and services. Moreover, government initiatives worldwide to control infectious diseases and rising investments & funding in healthcare infrastructure are expected to bolster the market growth in the APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antimicrobial Susceptibility Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antimicrobial Susceptibility Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Accelerate Diagnostics, Inc., Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE Tıbbi Malz. San. ve Tic. Ltd. Sti., BioMerieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, Danaher Corporation, ELITech Group SAS, Erba Lachema s.r.o., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Leading Biology, Inc., Liofilchem S.r.l., Mast Group Ltd., MP Biomedicals, LLC, Pfizer Inc., Qiagen N.V., QuantaMatrix Inc., Rapid Test Methods Ltd., Resistell AG, Synoptics Group, Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product Type
- Automated Products
- Consumables
- Manual Products
  - Minimum Inhibitory Concentration (MIC) Strips
  - Susceptibility Discs
  - Susceptibility Plates
Method
- Agar Dilution
- Disks Diffusion
- ETEST
- Genotyping Methods
- Rapid Automation Method
Type
- Antibacterial Susceptibility Testing
- Antifungal Susceptibility Testing
- Antiparasitic Susceptibility Testing
Application
- Clinical Diagnostics
- Drug Discovery & Development
- Epidemiology
End-User
- Contract Research Organizations
- Hospital & Diagnostic Centers
- Pharmaceutical & Biotechnology
- Research & Academic Institutes
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antimicrobial Susceptibility Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antimicrobial Susceptibility Testing Market?

3. What are the technology trends and regulatory frameworks in the Antimicrobial Susceptibility Testing Market?

4. What is the market share of the leading vendors in the Antimicrobial Susceptibility Testing Market?

5. Which modes and strategic moves are suitable for entering the Antimicrobial Susceptibility Testing Market?

Product Code: MRR-464C422F4BF4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Antimicrobial Susceptibility Testing Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Importance of antimicrobial susceptibility testing in medical decision-making
  - 5.1.1.2. Favorable government initiatives aiming to combat and prevent infectious diseases
- 5.1.2. Restraints
  - 5.1.2.1. High cost of antimicrobial susceptibility kits and lack of skilled professionals
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research on nanoparticles-based antimicrobial susceptibility testing
  - 5.1.3.2. Introduction of new genomic identification methods and launch of antimicrobial susceptibility test kits
- 5.1.4. Challenges
  - 5.1.4.1. Incidence of product recalls and strict regulations regarding antimicrobial susceptibility testing commercialization
5.2. Market Segmentation Analysis
- 5.2.1. Product Type: Advancement in the automated tools and consumables for early diagnosing and treatment of the infectious diseases
- 5.2.2. Method: Development of qualitative AST techniques with increased accuracy of the tests
- 5.2.3. Type: Significant advancements in antifungal susceptibility testing due to heightened awareness of invasive fungal infections
- 5.2.4. Application: Rapid and extreme utilization of the AST in clinical diagnostics and drug discovery and development
- 5.2.5. End-User: Extensive use of AST in hospitals and diagnostic laboratories
5.3. Market Trend Analysis
- 5.3.1. Government programs and significant research activities to develop antimicrobial susceptibility tests in the Americas.
- 5.3.2. Emphasis on the antibiotic susceptibility testing research and development programmes to treat and diagnose highly prevalent communicable diseases in APAC
- 5.3.3. Significant funding for antibiotic susceptibility testing and support from regulatory agencies in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter's Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework

6. Antimicrobial Susceptibility Testing Market, by Product Type

6.1. Introduction
6.2. Automated Products
6.3. Consumables
6.4. Manual Products
- 6.5.1. Minimum Inhibitory Concentration (MIC) Strips
- 6.5.2. Susceptibility Discs
- 6.5.3. Susceptibility Plates

7. Antimicrobial Susceptibility Testing Market, by Method

7.1. Introduction
7.2. Agar Dilution
7.3. Disks Diffusion
7.4. ETEST
7.5. Genotyping Methods
7.6. Rapid Automation Method

8. Antimicrobial Susceptibility Testing Market, by Type

8.1. Introduction
8.2. Antibacterial Susceptibility Testing
8.3. Antifungal Susceptibility Testing
8.4. Antiparasitic Susceptibility Testing

9. Antimicrobial Susceptibility Testing Market, by Application

9.1. Introduction
9.2. Clinical Diagnostics
9.3. Drug Discovery & Development
9.4. Epidemiology

10. Antimicrobial Susceptibility Testing Market, by End-User

10.1. Introduction
10.2. Contract Research Organizations
10.3. Hospital & Diagnostic Centers
10.4. Pharmaceutical & Biotechnology
10.5. Research & Academic Institutes

11. Americas Antimicrobial Susceptibility Testing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antimicrobial Susceptibility Testing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antimicrobial Susceptibility Testing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
- 14.3.1. Merger & Acquisition
  - 14.3.1.1. Bio-Rad Acquires Curiosity Diagnostics
- 14.3.2. Agreement, Collaboration, & Partnership
  - 14.3.2.1. JMI Laboratories and bioMerieux Enter Antimicrobial Resistance Diagnostics Partnership
  - 14.3.2.2. FASTinov Collaborates With Beckman Coulter Life Sciences To Bring Ultra-Rapid 2h-AST Disruptive Technology To Clinical Microbiology Laboratories
  - 14.3.2.3. BD Enters Commercial Collaboration With Accelerate Diagnostics
- 14.3.3. New Product Launch & Enhancement
  - 14.3.3.1. Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
  - 14.3.3.2. Sysmex Launches World's First Point-of-Care Testing System in Europe to Detect Antimicrobial Susceptibility in Just 30 Minutes
- 14.3.4. Investment & Funding
  - 14.3.4.1. Strathclyde spin-out Microplate dx secures GBP 2.5 million in funding
  - 14.3.4.2. Pattern Bioscience Secures USD 28.7 Million in Series C Financing
  - 14.3.4.3. Resistell raises CHF 8.5 million to complete clinical trials for antibiotic susceptibility testing
  - 14.3.4.4. Avails Medical, A Developer 0f Automated and Fully Electrical Antibiotic Susceptibility Testing (East) has Announced the Transition to The Next Phase of Its Carb-X Grant.
- 14.3.5. Award, Recognition, & Expansion
  - 14.3.5.1. Gradientech Welcomes Investment From Commercial Partner
  - 14.3.5.2. bioMerieux's Submits Vitek Reveal to FDA for Clearance
  - 14.3.5.3. Selux Diagnostics Secures FDA Approval For Its Rapid Antibiotic Susceptibility Test
  - 14.3.5.4. FDA clears rapid antibiotic susceptibility test

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. Accelerate Diagnostics, Inc.
- 15.1.2. Alifax S.r.l.
- 15.1.3. Becton, Dickinson and Company
- 15.1.4. Bio-Rad Laboratories, Inc.
- 15.1.5. BIOANALYSE Tıbbi Malz. San. ve Tic. Ltd. Sti.
- 15.1.6. BioMerieux SA
- 15.1.7. Biosafe Ltd.
- 15.1.8. Bruker Corporation
- 15.1.9. Creative Diagnostics
- 15.1.10. Danaher Corporation
- 15.1.11. ELITech Group SAS
- 15.1.12. Erba Lachema s.r.o.
- 15.1.13. Eurofins Scientific SE
- 15.1.14. F. Hoffmann-La Roche AG
- 15.1.15. Genefluidics, Inc.
- 15.1.16. Himedia Laboratories Private Limited
- 15.1.17. INTEGRA Biosciences AG
- 15.1.18. Laboratorios Conda, S.A.
- 15.1.19. Launch Diagnostics Limited
- 15.1.20. Leading Biology, Inc.
- 15.1.21. Liofilchem S.r.l.
- 15.1.22. Mast Group Ltd.
- 15.1.23. MP Biomedicals, LLC
- 15.1.24. Pfizer Inc.
- 15.1.25. Qiagen N.V.
- 15.1.26. QuantaMatrix Inc.
- 15.1.27. Rapid Test Methods Ltd.
- 15.1.28. Resistell AG
- 15.1.29. Synoptics Group
- 15.1.30. Thermo Fisher Scientific Inc.
- 15.1.31. Zhuhai DL Biotech Co., Ltd.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing